Oxford University Press, The Oncologist, 12(27), p. e977-e978, 2022
DOI: 10.1093/oncolo/oyac215
Export citation
Search in Google Scholar
Full text: Download
This letter to the editor responds to comments from Rizzo et al on recently reported results of a phase II study of dovitinib therapy for hepatocellular carcinoma.